Get the latest tech news
What good are whizzy new drugs if the world can't afford them?
Bringing gene therapies and obesity drugs to the masses will require financial innovation too, says Steven Pearson
Gene therapies for rare conditions and obesity drugs for larger segments of society could transform health for the better. But for that to happen, policymakers and the companies behind these new treatments need to adapt quickly to the daunting cost challenges associated with them. Seventeen single-dose therapies have been approved in America, with more than 80 expected by 2032.
Or read this on Hacker News
